Pain Sample Clauses

Pain. She states that she suffers from significant and frequent pain from a number of sources which is intense and sometimes almost unbearable.

Pain. Pain that interferes with swallowing, eating, or other normal activities requires expeditious (i.e., within 24 hours) treatment by a dentist, physician, or appropriately trained MLP. As with dentoalveolar infections, the inmate may be triaged and stabilized by MLPs or physicians and seen by the dentist at dental sick call. The system must be designed to allow for inmates to be seen within 24 hours for stabilization of their pain and an evaluation of its source. Pain associated with denture irritation can be stabilized by leaving the denture out until the inmate may be seen by a dentist. Level two is primarily associated with the dental daily sick call or other requests for urgent care. Inmates with intermittent or constant pain, an inability to eat, and other dental symptoms that cause discomfort should have access to assessment and the initiation of treatment within 24 hours by a dentist, physician, or appropriately trained MLP. Examples of Level 2 care are toothaches, infections, and pain of apparent maxillofacial origin. Level 3 is disease control or routine care. The acute problems have been stabilized in Levels 1 and 2. Inmates who enter this level require a comprehensive treatment plan. When an inmate progresses to Level 3, he should be free from infection; and pain that interferes with normal daily activities. Carious lesions progress slowly and an early lesion takes several years to progress through the enamel of a permanent tooth.

Pain. Discomfort associated with DC injections is normal and usually of a short duration. It is possible to have a fainting episode (vasovagal) from discomfort or anxiety about the injections. Procedural discomfort is managed with oral pain medicine, local anesthesia injections before DC is injected, and over the counter analgesics. Complications (adverse events) Potential complications attributable to the injection of DC for fat reduction in the chin and jawline are: Damage to Marginal Mandibular Nerve - DC injections in the area of the marginal mandibular nerve, which is located in the vicinity of the jaw bone can occur. This would produce diminished motion in the corner of the mouth. According to data from the research on DC, this is a rare complication and generally resolves over time. Difficulty to swallow - Difficulty to swallow has been reported in a few patients that have undergone DC injections. Typically, this resolves. Individuals who have a history of swallowing difficulties may not be suitable for DC injections. Infection - Although infection following injection of DC is unusual, bacterial, fungal, and viral infections can occur. Should any type of skin infection occur, additional treatment including antibiotics may be necessary. Damage to deeper structures - Deeper structures such as nerves, salivary glands, and the neck muscles may be damaged during the course of injection. Injury to deeper structures may be temporary or permanent. Temporary numbness can occur in the area where DC is injected. Skin Necrosis - It is very unusual to experience death of skin and deeper soft tissues after DC injections. Skin necrosis can produce unacceptable scarring. Should this rare complication occur, additional treatments, or surgery may be necessary. Granulomas and Fat Necrosis - Painful masses in the skin and deeper tissues after a DC injection are extremely rare. Should these occur, additional treatments including antibiotics or surgery may be necessary. These may produce scarring within the skin and deeper structures. Allergic Reactions and Hypersensitivity - As with all injectable products, allergic reactions may occur. Allergic reactions may require additional treatment. It is unknown if DC is associated with serious systemic anaphylactic allergic reactions. Accidental Intra-arterial injection - One of the risks with using this product is unintentional injection into a blood vessel. The chances of this happening are very small and may not be of consequence, ...

Pain. Published online 2003. doi:10.1016/S0304-3959(02)00484-0

Pain. Pain is a protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses can be mounted. The National Institutes of Health (the “NIH”) defines chronic pain as pain that persists beyond the normal healing time of an injury or that persists longer than three months. It is estimated that chronic pain affects 100 million individuals in the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease, and cancer combined (▇▇▇▇▇ Therapeutic Categories Outlook, March 2019). Chronic pain exacts a tremendous cost in terms of direct treatment and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public health problem in the United States that costs society between $560 billion and $635 billion annually. Despite the magnitude of the pain problem, innovation in the development of therapeutic solutions has been largely absent. Since 2010, there have been 20 approvals by the FDA for the treatment of pain, of which 12 were opioid variants, one was an extended-release generic corticosteroid, five were variants of aspirin, and two were variants of other existing drugs. We are developing a novel product candidate designed to overcome the limitations of current treatment options for patients with PAD who suffer from chronic pain. According to a research study by Stanford University, more than 24% of patients with PAD are at risk of high opioid use. By treating pain at the source and presenting patients and physicians with better and safer treatment alternatives, we expect to minimize opioids at the prescription pad. Given the properties of JAN101, we have made the strategic decision to focus initially on pain associated with PAD by treating the underlying cause of PAD. Peripheral artery disease (“PAD”) is a general term for conditions in which arterial blood flow to the limbs is partially blocked. When there is less blood present in the extremities relative to demand, muscle pain and fatigue result, especially in the calf, which is also known as “intermittent claudication.” In many patients, pain and fatigue are relieved through rest. Roughly half of patients with PAD are asymptomatic. The most common cause of PAD / intermittent claudica...

Pain. Usually peaks in the first 2 days following surgery and can be controlled by the medication that ▇▇. ▇▇▇▇▇ recommends (e.g. Advil/Motrin [ibuprofen]) or prescribes. They may be taken to relieve the pain (please read the package insert for dosages). These medications when taken on an empty stomach can cause stomach upset, nausea, etc. Please try to take your pain medication with food or fluids.

Pain. If [*] differ from conditions in [*], then the criteria for the [*].

Pain. The International Association for the Study of Pain (IASP) defines pain as “an unpleasant sensory and emotional experience associated with actual and potential tissue damage” (Derbyshire, 1999). Research has illustrated that there is a significant degree of subjectivity to the nature of pain experience, which includes both the central and the peripheral nervous systems, influenced by multiple pain-modulating factors such as past painful experience, cognitive components and the emotional state of an individual (▇▇▇▇▇▇▇, 2013). There is also enormous variability among individual’s pain experiences (▇▇▇▇▇▇ et al., 2012b). Pain is activated through special receptors called nociceptors, which recognize actual or potential tissue damage (Hall and ▇▇▇▇▇▇, 2011). Pain that lasts and or recurs for more than three months or beyond the time of recovery is chronic pain (Merskey and ▇▇▇▇▇▇, 1994a). In chronic pain conditions, physiochemical changes occur within the neural pathways, making them hypersensitive to pain stimuli and the signals are repeatedly triggered. (▇▇▇▇▇▇▇▇, 2000). Persistent pain impacts all domains of life, such as disturbed sleep, lack of concentration, mood disorders and feeling fatigued, frustrated, and anxious. The stress and depression generate family and employment issues resulting in a substantial burden on the healthcare system (Turk and Okifuji, 2002). The prevalence of chronic pain, in general, is 43% in the UK; this equates to approximately just under 28 million of the UK population (▇▇▇▇▇ et al., 2016). According to a Canadian 2007/2008 pain survey, there is a reduced quality of life in more than 50% of individuals with pain, a negative impact on relationships of almost 29% and job loss or taking up less responsibilities for more than 50% of chronic pain patients (▇▇▇▇▇▇, 2011). Chronic pain conditions, in general, produce a significant degree of disability (Breivik et al., 2013) in the sufferer and are responsible for 21% of visits to the accident and emergency department and 25% of absenteeism from work annually (▇▇▇▇▇▇▇ and ▇▇▇▇▇▇▇, 2012).

Pain. Author manuscript; available in PMC 2016 December 01. Author Manuscript Published in final edited form as: